Head and neck squamous cell cancer and the human papillomavirus: Summary of a National Cancer Institute State of the Science Meeting, November 9–10, 2008, Washington, D.C.
David J. Adelstein(Cleveland Clinic), Claudio Dansky Ullmann(Multimeric Biotherapeutics (United States)), Anil K. Chaturvedi(National Cancer Institute), Gypsyamber DʼSouza(Johns Hopkins University), William H. Westra(Mount Sinai Hospital), Steven H. Krosnick(National Cancer Institute), Arlene A. Forastiere(Greater Baltimore Medical Center), W. Martin Kast(University of Southern California), Andy Trotti, John A. Ridge(Fox Chase Cancer Center), Amanda Psyrri(National and Kapodistrian University of Athens), Maura L. Gillison(The University of Texas MD Anderson Cancer Center), Anna R. Giuliano(Moffitt Cancer Center), Laura A. Koutsky(Fred Hutch Cancer Center), David E. Schuller(Ohio State University Hospital), Patti E. Gravitt(Praxis)
Cited by 265
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Human Papillomavirus and Rising Oropharyngeal Cancer Incidence in the United States
|Journal of Clinical Oncology|2011|3.6k
Postoperative Concurrent Radiotherapy and Chemotherapy for High-Risk Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2004|3.2k